[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-stage-ovarian-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-stage-ovarian-tumors":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100632024","patent-blue-sln-in-early-ovarian-cancer-prospective-study-figo-i-ii-evaluating-patent-blue-sln-mapping-injection-into-ipuo-ligaments-in-situ-goals-assess-feasibility-and-accuracy-vs-standard-lymphadenectomy-to-minimize-surgical-morbidity-100632024",false,"NCT07508306","Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP\u002FUO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity","Evaluation of Sentinel Lymph Node Biopsy Using Patent Blue Dye in Early-Stage Ovarian Cancer: A Prospective Observational Study","Inclusion Criteria:\n\n* Age : aged 18 years-old or older\n* Diagnosis: Suspected Ovarian cancer on MRI finding (O-RADs 4 or 5)\n* FIGO stage: Stage I or II ( Based on MRI and scanner finding)\n* Planned Procedure: Patients with planned for surgical complete stadification including pelvic and para-aortic lymphadenectomy\n* Consent: Signing of the written informed consent after full information has been provided\n\nExclusion Criteria:\n\n* Suspicious nodal involvement: Presence of suspicious lymph nodes on preoperative imaging (generally defined by a short-axis diameter ≥ 10 mm).\n* Disease extension: Radiological or intraoperative evidence of extra-pelvic metastases or peritoneal carcinomatosis.\n* Surgical history: History of lymphadenectomy, lymph node sampling, or major vascular surgery involving the aorta or the iliac vessels.\n* History of radiotherapy: Patients who have previously undergone pelvic or abdominal radiotherapy.\n* Allergies: Known allergy or adverse reaction to patent blue dyes.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","6 Months","OBSERVATIONAL","the standard of care in case of early ovarian cancer (stage I or II) is a complete surgery. This surgery includes : hysterectomy (remove of the uterus), bilateral salpingo-oophorectomy (remove of the adnexa), omentectomy (remove of the epiploon), bilateral pelvic lymphadenectomy (remove of pelvic lymph nodes) and para-aortic lymphadenectomy (remove of para-aortic lymph nodes). This procedure is diagnostic, curative and prognostic surgery. In fact, it allows us provider care giver to stratify the stage of the cancer, hence we give the appropriate adjuvant therapy.\n\nHowever, this surgery, especially the extended lymphadenectomy, is associated with some risks: lymphocele, vessel injury, blood loss, morbidity, long recovery period ... In order to reduce these risks, we propose a sentinel lymph node biopsy. This intervention allows us to detect first lymph node relay whether pelvic or para-aortic.\n\nIn our study, we chose the patent blue dye as a tracer. This tracer is widely used in oncologic surgery (for example in breast cancer) and approved but not in ovarian cancer yet.\n\nDuring surgery for early stage ovarian cancer, we will inject the patent blue dye on both side of the ovarian tumor. Then, we will check for first colorful lymph node, in both pelvic and para-aortic regions. We will send these dissected lymph node to pathology for analysis. Finally, we will continue the procedure as the standard of care.\n\nOur objective is to compare the results between the sentinel lymph node and the complete lymphadenectomy and to study the technique of sentinel lymph node biopsy using the blue patent dye as tracer.",[25,26],"Sentinel Lymph Node Biopsy (SLNB)","Early Stage Ovarian Tumors",[28,29,30,31],"early stage ovarian cancer","sentinel lymph node","sentinel lymph node biopsy","Patent blue dye","RECRUITING","2026-03-31",{"date":35,"type":36},"2026-04-02","ACTUAL",{"date":38,"type":20},"2026-04-15",{"date":40,"type":20},"2028-02-28",{"name":42,"class":43},"Faculty of Medicine of Tunis","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100613847","ponder-pelvic-peritonectomy-in-early-stage-ovarian-tumors-100613847","NCT07271914","PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors","Pelvic peritOnectomy iN Early Stage Ovarian Tumors: a prospEctive Study","PONDER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* FIGO 2018 stage IA-IB epithelial or non-epithelial ovarian or fallopian tube tumors\n* Complete preoperative work-up (ultrasound, CT scan, tumor markers)\n* Laparoscopic, robotic or open surgical approach\n* Signed informed consent\n\nExclusion Criteria:\n\n* Sarcomas, melanomas, mesotheliomas, hematologic malignancies\n* Advanced ovarian tumors\n* Fertility-sparing surgery with uterine preservation\n* Inability to provide informed consent",{"count":54,"type":20},390,"INTERVENTIONAL",[57],"NA","Early-stage ovarian tumors represent approximately 30% of all newly diagnosed ovarian cancers. Current international guidelines recommend random peritoneal biopsies for surgical staging, but the diagnostic yield of these biopsies remains limited. The PONDER study aims to evaluate whether standardized surgical procedure and pathology assessment of wider peritoneal pelvic biopsies can increase the detection rate of microscopic peritoneal implants and micrometastases in patients with early-stage ovarian tumors. This multicenter, prospective, single-arm study includes both minimally invasive and open surgical approaches, with a standardized gross and microscopic evaluation of the resected peritoneal specimens",[26,60],"Peritoneal Carcinosis",[62,63,64,65,66],"ovarian cancer","early stage","ovarian tumor","peritoneal carcinosis","pathology assessment","NOT_YET_RECRUITING","2025-11-26",{"date":70,"type":36},"2025-12-09",{"date":72,"type":20},"2026-02",{"date":74,"type":20},"2032-08",{"name":76,"class":43},"Ospedale Santa Croce-Carle Cuneo"]